<?xml version="1.0" encoding="UTF-8"?>
<p id="JVEv5-para-0109">Massimo Levrero (University of Lyon, France) discussed the difficulty of defining HBV cure. He noted that there are many barriers to HBV cure when using currently available drugs in the context of cccDNA stability, integrated HBV DNA and a defective immune response to the virus in chronic carriers, none of which are directly addressed with current therapeutic strategies.</p>
